Related Experiment Video
Updated: Sep 9, 2025
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
1.5K
Discovery, Optimization, and Evaluation of Non-Nucleoside SARS-CoV-2 NSP14 Inhibitors
Michael W Miller1, Cindy Meyer2, Aitor Garzia2
1Sanders Tri-Institutional Therapeutics Discovery Institute, The Rockefeller University, 1230 York Avenue, New York, New York 10065, United States.
Journal of Medicinal Chemistry
|September 5, 2025
Summary
We discovered TDI-015051, a novel small-molecule inhibitor targeting SARS-CoV-2
Area of Science:
- Virology
- Medicinal Chemistry
- Drug Discovery
Background:
- SARS-CoV-2 nonstructural protein 14 (NSP14) is essential for viral RNA synthesis.
- NSP14's guanine-N7 methyltransferase activity is a potential target for antiviral therapies.
- Inhibiting viral methyltransferases offers a novel antiviral strategy.
Purpose of the Study:
- To identify and characterize small-molecule inhibitors of SARS-CoV-2 NSP14.
- To validate SARS-CoV-2 NSP14 as a drug target for COVID-19 treatment.
- To demonstrate the pharmacological inhibition of viral methyltransferases.
Main Methods:
- Structure-activity relationship (SAR) studies were conducted.
- High-throughput screening (HTS) identified initial hits.
- Thermal shift assays and X-ray crystallography were used to analyze inhibitor binding.
Main Results:
- Potent non-nucleoside inhibitors with single-digit nanomolar cellular activity were developed.
- A model of the inhibitory ternary complex (NSP14, SAH, inhibitor) was established and validated.
- Proof-of-concept studies confirmed NSP14 as a viable drug target.
Conclusions:
- SARS-CoV-2 NSP14 is a validated drug target for COVID-19.
- Pharmacological inhibition of viral methyltransferases is a promising antiviral therapeutic approach.
- TDI-015051 represents a first-in-class inhibitor of SARS-CoV-2 NSP14.
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
15.8K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.8K
01:26Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K